MULTIPLE SCLEROSIS, PARKINSON’S DISEASE AND ALS AMONG DISEASES ADDRESSED IN STEM CELL PHARMA INC.’S NEW EXECUTIVE SUMMARY
Las Vegas, Nv. 8/29/2007 5:34 PM GMT (FINDITT)
The following is the new Executive Summary posted on the Stem Cell Pharma, Inc. (SCPI) website.
STEM CELL PHARMA INC. (SCPI)
Stem Cell Pharma Inc. (SCPI) is a privately held bio-pharmaceutical company founded in May of 2005, with a capitalization of 10 mm shares, out of which 3.3mm are issued and outstanding.
SCPI owns the world wide rights to an Invention "An Amniotic Membrane Stem Cell Telomerase Enhanced Implant, Manufacturing And Clinical Uses" by Alfred T. Sapse MD (r) its President and Founder. This invention is a novel approach to harvest embryonic type stem cells from the amniotic membrane, a translucid sheet covering placenta. These embryonic cells can potentially repair and if needed rebuild practically all organs, tissues and cells, through a process of differentiation, once introduced in the human body.
The implant had been used with modest to substantial results in the treatment of neuro degenerative diseases such a Multiple Sclerosis (MS), ALS (Lou Gehrig's Disease), Parkinson's, in eye diseases (Retinitis Pigmentosa - RP, Usher's Syndrome - RP plus deafness), Muscular Dystrophy (MDA) including Duchenne's, children diseases such as Cerebral Palsy (CP) and Epilepsy, autoimmune (Lupus Erythematosus (LE)), and especially in the treatment of symptoms of aging. Clinical studies commenced in the US are now being carried out abroad and some of the results obtained might be used in the United States in the future IND's submissions to the FDA. There were no reports about infections and rejections or any side effects after the use of the implant.